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We aimed to investigate the impact of high-fat low-cholesterol diets rich in 27	
saturated fatty acids (HFLCD-SFAs), monounsaturated FAs (HFLCD-MUFAs) 28	
or MUFAs + omega-3 long-chain polyunsaturated FAs (HFLCD-PUFAs) in 29	
combination with niacin (NA) on atherosclerotic plaque characteristics in a 30	
mouse model (Lepob/obLDLR−/−) of metabolic syndrome (MetS). Compared to 31	
a low-fat low-cholesterol diet (LFLCD), HFLCDs increased body weight, 32	
triglycerides, insulin, pro-inflammatory cytokines, and circulating monocytes, 33	
contributing the HFLCD-SFAs to a predominance of a classical pro-34	
inflammatory Ly6Chi population, whereas HFLCD-MUFAs and HFLCD-PUFAs 35	
to a non-classical patrolling Ly6Clo population. HFLCDs promoted 36	
atherosclerosis in the aortic roots of animals but the plaque size, collagen, 37	
and macrophage content were higher with the HFLCD-SFAs than with the 38	
HFLCD-MUFAs or HFLCD-PUFAs. Furthermore, HFLCD-SFAs promoted the 39	
intra-plaque accumulation of M1 macrophages, whereas HFLCD-MUFAs and 40	
HFLCD-PUFAs favoured the accumulation of M2 macrophages. These data 41	
suggest that dietary MUFAs had advantage over SFAs to prevent 42	
atherosclerotic events in the NA-treated MetS. 43	
 44	
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Dyslipidemia, insulin resistance, and obesity, the defining components of the 52	
metabolic syndrome (MetS), are well-known risk factors implicated in the 53	
aetiology and pathogenesis of certain cardiovascular diseases (CVDs) such 54	
as atherosclerosis, the main cause of CVD death in developed and some 55	
developing countries (Libby, 2012). Atherosclerosis is a systemic lipid-driven 56	
inflammatory condition associated with endothelial dysfunction that results in 57	
accumulation and subsequent oxidation of lipids in the vessel wall or plaque 58	
development. These abnormalities trigger inflammatory cell infiltration and 59	
macrophage foam cell formation leading to apoptosis and secondary necrosis 60	
and plaque advancement (Tabas, 2010). It is important to address the factors 61	
involved in the progression of atherosclerosis because advanced 62	
atherosclerotic lesions are prone to rupture, leading to disability or death. The 63	
monocyte-macrophage lineage is of fundamental interest in understanding 64	
atherosclerotic lesion progression (Ziegler-Heitbrock et al., 2010). Monocytes 65	
can be found into two distinct subsets based on the expression of specific 66	
surface markers. In mice, monocytes are divided based on Ly6C expression 67	
into inflammatory Ly6C high (Ly6Chi) and patrolling Ly6C low (Ly6Clo) 68	
monocytes (Auffray et al., 2007; Sunderkotter et al., 2004). CC-motif 69	
chemokine receptor 2 (CCR2) is expressed at high levels by inflammatory 70	
monocytes (Zlotnik & Yoshie, 2000), whereas CX3C-motif chemokine receptor 71	
1 (CX3CR1) is more abundant on patrolling monocytes (Geissmann, Jung, & 72	
Littman, 2003; Woollard & Geissmann, 2010). Inflammatory monocytes are 73	
generally thought to be the most important subtype in early atherogenesis, 74	
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being efficiently recruited to the lesion in a CCR2-dependent manner 75	
(Robbins et al., 2012; Soehnlein et al., 2013). 76	
 77	
The atheroprotective effects of niacin (NA), also known as nicotinic acid or 78	
vitamin B3, were first described in the 1950s (Carlson, 2005; Montserrat-de la 79	
Paz et al., 2016a). According to a meta-analysis of 30 randomized controlled 80	
trials, NA potently reduces triglycerides (TGs) by 15-30%, total cholesterol 81	
(TC) by 5-15%, and LDL-cholesterol (LDL-C) by 5-20% and increases HDL-82	
cholesterol (HDL-C) by 10-25% in plasma of patients with dyslipidaemia 83	
and/or hypercholesterolemia (Birjmohun, Hutten, Kastelein, & Stroes, 2005). 84	
Additional to the pharmacology of NA, several translational studies have 85	
identified the differential role between saturated and unsaturated fats at 86	
cardiovascular level. Compared to saturated fatty acids (SFAs), the 87	
consumption of monounsaturated (MUFAs) and omega-3 long-chain 88	
polyunsaturated (PUFAs) fatty acids have beneficial effects on lowering blood 89	
lipids (Ortega et al., 2012; Vafeiadou et al., 2015) and inflammatory mediators 90	
(Naranjo et al., 2016;Teng, Chang, Chang, & Nesaretnam, 2014). However, 91	
the potential anti-atherogenic effects from a combination of dietary fatty acids 92	
and NA have not yet been defined. Therefore, the current study aimed to 93	
explore the influence of a pharmacological dose of NA and diets enriched in 94	
SFAs, MUFAs or MUFAs + omega-3 long-chain PUFAs on atherosclerosis in 95	
a mouse model (Lepob/obLDLR−/−) of MetS. 96	
 97	
2. Materials and methods 98	
2.1. Fatty acid composition of dietary fats 99	
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The fatty acid composition of dietary fats [cow's milk cream, rich in SFAs; 100	
refined olive oil, rich in MUFAs; and refined olive oil plus eicosapentaenoic 101	
acid (EPA) and docosahexaenoic acid (DHA), rich in MUFAs and omega-3 102	
long-chain PUFAs] was determined by the method described in 103	
EEC/796/2002 (Montserrat-de la Paz et al., 2016b), using a gas 104	
chromatography system (HP-5890, Hewlett-Packard, Palo-Alto, USA) 105	
equipped with flame ionization detector and a SP-2380 capillary column 106	
(Supelco, Bellefonte, USA, 30 m x 0.32 mm) packed with cyanopropyl 107	
siloxane (0.25 µm). The initial column temperature was 165 ºC, which was 108	
held for 10 min, then programmed from 165 ºC to 200 ºC at 1.5 ºC/min. 109	
Injector and detector temperature were 250 ºC, with the carrier gas H2. The 110	
fatty acid composition of different dietary fats is detailed in Table 1. 111	
 112	
2.2. Animal diets and experimental design 113	
Male Lepob/obLDLR−/− mice bred onto a C57BL/6J background (B6.Cg-Lepob 114	
Ldlrtm1Her/J, The Jackson Laboratory, Bar Harbor, ME, USA) was used for 115	
the study. These mice are obese and develop plasma lipid alterations that 116	
closely reflect MetS-related hyperlipidaemia (Kennedy et al., 2010; 117	
Montserrat-de la Paz et al., 2016c). All diets were prepared by Panlab 118	
Laboratoires (SAFE, Augy, France) and presented as pellets to the animals. 119	
Mice received one of the following diets for 8 weeks: a standard normal-fat 120	
diet (low-fat low-cholesterol diet, LFLCD) containing 3% energy as fat, used 121	
as control, or high-fat low-cholesterol diets (HFLCDs), which contained 24% 122	
energy as fat. All the diets were based on the standard rodent diet A04-10, 123	
containing 0.01% cholesterol, 20 mg/kg BHT, and 3% binder. Three different 124	
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HFLCDs were prepared by replacing the fat source from A04-10 diet by cow's 125	
milk cream (21% energy) (HFLCD-SFAs), refined olive oil (21% energy) 126	
(HFLCD-MUFAs) or refined olive oil (20% energy) plus EPA+DHA in the form 127	
of ethyl esters (1% energy) (HFLCD-PUFAs). The cow’s milk cream provided 128	
an additional amount of 0.006% by weight. All the diets contained equal 129	
proportion of protein (19.5% energy) and carbohydrate was used to adjust the 130	
total energy content. 131	
 132	
After weaning, mice were randomly allocated into 4 groups (n = 10 per group) 133	
as follows: (1) group that received LFLCD; (2) group that received HFLCD-134	
SFAs; (3) group that received HFLCD-MUFAs; and (4) group that received 135	
HFLCD-PUFAs. The four groups received NA (1%, w/v; Twinlab, UT, USA) in 136	
the drinking water. Body weight, food, and water intake were daily evaluated. 137	
Sacrifice of all animals was carried out within the animal facilities (Instituto de 138	
Biomedicina de Sevilla, IBiS), at the beginning of the light cycle and after 10 h 139	
of food deprivation. Animals were euthanized with an overdose of 140	
pentobarbital (1:10 in PBS, 150 mg/kg body weight). Cardiac puncture was 141	
used to blood collection. Heart samples were collected upon sacrifice. All 142	
animal protocols received appropriate institutional approval (Animal Care and 143	
Use Committee of the University of Seville) and were performed according to 144	
the official rules formulated in the Spanish law on the care and use of 145	
experimental animals (UE Directive of 2010: 2010/63/UE; RD 53/2013). 146	
 147	
2.3. Biochemical parameters 148	
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Serum samples were obtained from blood by centrifugation at 1800 g for 15 149	
min at 4 ºC. Fasting serum levels of glucose, TC, and TGs were assessed by 150	
colorimetric assay kits (Bio-science-medical, Madrid, Spain). Serum cytokines 151	
were measured using Multiplex Biomarker Immunoassays for Luminex xMAP 152	
technology (Millipore, Billerica, USA). 153	
 154	
2.4. Immunostaining of circulating monocytes by FACS 155	
Cardiac blood samples were collected at the end of each dietary period. 156	
Circulating monocyte membrane expression of CD11b (PerpCy5.5 anti-mouse 157	
CD11b, Becton Dickinson, Oxford, UK), Ly6G (FITC anti-mouse Ly6G, 158	
Miltenyi, Madrid, Spain), Ly6C (APC-Cy7 anti-mouse Ly6C, Miltenyi), CCR2 159	
(APC anti-mouse CCR2, Miltenyi), and CX3CR1 (PE-Cy7 anti-mouse 160	
CX3CR1, BD) was assessed by flow cytometry. Cells were incubated with 161	
antibodies at room temperature, in the dark, for 15 min, followed by fixation 162	
and lysing of erythrocytes with 20× volume of Fluorescence Activated Cell 163	
Sorting (FACS) lysing solution (BD). Fluorescence intensity was measured by 164	
using a FACSCanto II cytometer and calibrated using FACSCanto II Cell 165	
analyser software (BD). Mean fluorescence intensity (MFI) of 104 counted 166	
cells was measured in each sample. Monocytes were gated as forward 167	
scatterhigh (FSChi)-side scatterhigh (SSChi)-cells. Expression levels were 168	





Mouse heart was dissected, fixed in 1% paraformaldehyde, and embedded in 173	
paraffin. Size of atherosclerotic lesions was determined as previously 174	
described (Gijbels et al., 1999). Serial sections (6 µm) of the aortic root were 175	
cut and stained with haematoxylin-eosin (HE) for morphometric analysis and 176	
routine qualitative examination of collagen content, necrosis, and amount of 177	
inflammatory B (B220) and C (CD3) cells. Sirius Red was used for the 178	
detection of collagen. A polarized filter and birefringence colour discrimination 179	
was used to differentiate various collagen structures [ranging from loosely 180	
patched, immature, thin collagen (green) to tightly packed, mature, thick 181	
collagen fibres (red)] as previously described (Mackenna, Omens, & Covell, 182	
1996). For evaluation of macrophage content were used MAC3 (an antibody 183	
recognizing pan macrophages), CCR7 (antibody against M1 macrophages), 184	
and CD163 (antibody against M2 macrophages). Samples were captured at 185	
20× magnifications by a Leica DM3000 light microscope (Leica, Wetzlar, 186	
Germany) and an independent operator, in a blinder manner, performed 187	
histological analyses using Quantimet with Qwin3 quantification software 188	
(Leica). 189	
 190	
2.6. Statistical analysis 191	
All values in the figures and text are expressed as the arithmetic mean ± SD. 192	
Experiments were carried out in triplicate. Data were evaluated with Graph 193	
Pad Prism Version 5.01 software. The statistical significance of any difference 194	
in each parameter among the groups was evaluated by one-way analysis of 195	
variance (ANOVA), using Tukey's test for multiple comparison analysis. P 196	




3.1. MUFA-rich diets reduce body weight gain and serum TG, insulin, 200	
and pro-inflammatory cytokine levels compared to the SFA-rich diet in 201	
NA-treated Lepob/obLDLR−/− mice 202	
In the setting of NA treatment, mean daily food intake (LFLCD, 4.07 ± 0.32; 203	
HFLCD-SFAs, 4.15 ± 0.61; HFLCD-MUFAs, 4.01 ± 0.47; HFLCD-PUFAs, 204	
4.17 ± 0.41 g/mouse) and water intake (LFLCD, 6.28 ± 0.83; HFLCD-SFAs, 205	
6.35 ± 1.01; HFLCD-MUFAs, 6.12 ± 0.77; HFLCD-PUFAs, 6.11 ± 0.81 206	
mL/mouse) were not different among the four diet groups. Despite similarities 207	
in food and drink intake, the final body weight and body weight gain of animals 208	
increased but to a different degree depending on the diet (HFLCD-SFAs > 209	
HFLCD-MUFAs = HFLCD-PUFAs > LFLCD, Table 2). Serum TG levels were 210	
significantly higher in animals fed with HFLCDs (HFLCD-SFAs > HFLCD-211	
MUFAs = HFLCD-PUFAs) than in those fed with the LFLCD. Serum TC levels 212	
did not differ among the HFLCD groups but were higher than those observed 213	
in the LFLCD group. Notably, serum insulin levels were significantly different 214	
in all groups: HFLCD-SFAs > HFLCD-MUFAs > HFLCD-PUFAs > LFLCD. No 215	
differences were observed for serum glucose levels. In relation to pro-216	
inflammatory cytokines, serum TNF-α levels were higher only in animals fed 217	
with HFLCD-SFAs, whereas serum IL-6 and monocyte chemoattractant 218	
protein-1 (MCP-1/CCL2) levels were found to be higher in animals fed with 219	
HFLCDs (for IL-6, HFLCD-SFAs > HFLCD-MUFAs = HFLCD-PUFAs; for 220	
MCP-1, HFLCD-SFAs = HFLCD-MUFAs = HFLCD-PUFAs) than in those fed 221	
with the LFLCD. 222	
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 223	
3.2. MUFA-rich diets skew the frequency of circulating monocytes 224	
toward a CD11b+Ly6GloLy6CloCX3CR1hi patrolling subset compared to 225	
the SFA-rich diet in NA-treated Lepob/obLDLR−/− mice 226	
We examined the effects of the different diets on blood monocyte activation. 227	
CD11b+Ly6Glo monocytes were gated on Ly6C expression (Figure 1A). 228	
Animals on HFLCDs had a significant increase (P<0.05) of total circulating 229	
monocytes (960000 ± 109000 per mL after the HFLCD-SFAs; 900000 ± 230	
80000 per mL after the HFLCD-MUFAs; 920000 ± 100000 per mL after the 231	
HFLCD-PUFAs) when compared to animals fed with the LFLCD (600000 ± 232	
30000 monocytes/mL). This monocytosis resulted from a 60% of Ly6Clo 233	
subset after HFLCD-MUFAs and HFLCD-PUFAs (Figure 1B) and a 60% of 234	
Ly6Chi subset after the HFLCD-SFAs (data not shown). As depicted in Figure 235	
1C, total monocyte population from animals fed with HFLCD-MUFAs and 236	
HFLCD-PUFAs had increased CX3CR1 expression. These monocytes also 237	
had lower CCR2 expression than those of animals fed with the HFLCD-SFAs 238	
(Figure 1D). 239	
 240	
3.3. MUFA-rich diets lead to a lesser atherosclerotic lesion size and 241	
collagen content compared to the SFA-rich diet in NA-treated 242	
Lepob/obLDLR−/− mice 243	
All of the HFLCDs induced plaque formation in aortic roots of animals when 244	
compared to the LFLCD, but this effect was more marked with the HFLCD-245	
SFAs than with HFLCD-MUFAs or HFLCD-PUFAs (Figure 2A). After HFLCD-246	
MUFAs and HFLCD-PUFAs, the plaque size by means of HE staining was 247	
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half the plaque size after the HFLCD-SFAs (Figure 2B). Atherosclerotic 248	
lesions were further examined for collagen and adventitial inflammatory cell 249	
content and for necrosis. Any atherosclerotic plaque had necrosis or 250	
adventitial infiltration of inflammatory cells (data not shown). However, the 251	
fibrosis by means of collagen content was dramatically increased in plaques 252	
of animals fed with HFLCDs (Figures 3A and 3B). Interestingly, HFLCD-253	
MUFAs and HFLCD-PUFAs induced plaques with half of collagen deposited 254	
in those induced by the HFLCD-SFAs (Figure 3C). Differentiating on the 255	
basis of collagen structure [loosely patched, immature, thin collage (green) 256	
versus tightly packed, mature, thick collagen fibres (red)] by using a 257	
polarization filter (Figure 3B), we observed that increased plaque fibrosis with 258	
the HFLCD-SFAs was concomitant with an increase in mature, thick collagen 259	
fibre content (Figure 3D). 260	
 261	
3.4. MUFA-rich diets favour alternatively activated macrophages in 262	
atherosclerotic plaques compared to the SFA-rich diet in NA-treated 263	
Lepob/obLDLR−/− mice 264	
Macrophage accumulation and phenotype in atherosclerotic plaques of 265	
animals fed with the different diets were determined by immunohistochemical 266	
staining of MAC3 (pan-macrophage marker) (Figure 4A), CCR7 (M1 267	
macrophage marker) (Figure 4B), and CD163 (M2 macrophage marker) 268	
(Figure 4C). It was noteworthy to observe a markedly increased accumulation 269	
of macrophages (Figure 4D), mainly of type M1 (Figure 4E), in plaques from 270	
animals fed with the HFLCD-SFAs. However, HFLCD-MUFAs and HFLCD-271	
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PUFAs promoted the intra-plaque accumulation of M2 macrophages when 272	
compared to the HFLCD-SFAs or LFLCD (Figure 4F). 273	
 274	
4. Discussion 275	
This study is the first to address the effects of predominant fatty acids in 276	
dietary fats and NA co-ingestion on atherosclerosis in mice. We used male 277	
mice homozygous for the ob/ob and Ldlrtm1Her targeted mutations lacking the 278	
hormone leptin and LDL receptor onto a C57BL/6J background. When 279	
subjected to a HFLCD rich in SFAs, these animals become obese, 280	
hyperinsulinemic, and develop severe dyslipidaemia, which are pathological 281	
manifestations analogous to those characteristics of human MetS (Git & 282	
Adan, 2015; Kennedy et al., 2010). In the setting of NA treatment, we 283	
demonstrate that compared to dietary SFAs, dietary MUFAs, accompanied or 284	
not with omega-3 long-chain PUFAs, confer atheroprotection by impacting on 285	
several hallmark processes directly associated with atherosclerosis: MUFAs + 286	
NA induced a less inflammatory cytokine profile; MUFAs + NA induced a 287	
mobilization of less inflammatory monocytes; MUFAs + NA favourably altered 288	
plaque size, fibrosis, and M1/M2 phenotype of recruited macrophages. In 289	
addition, the gain of body weight with HFLCDs rich in MUFAs was attended 290	
by lower serum lipid and insulin levels than with the HFLCD rich in SFAs, 291	
suggesting that MUFAs + NA also ameliorated some of the metabolic 292	
complications of the HFLCD-induced obesity. 293	
 294	
The persistence of circulating pro-inflammatory cytokines and chemokines 295	
may be harmful at multiple levels and at different stages of atherosclerosis 296	
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from early to advanced disease (Ait-Oufella et al., 2011). In contrast to the 297	
HFLCD rich in SFAs, we found that HFLCDs rich in MUFAs did not alter 298	
serum TNF-α levels and minimally increased serum IL-6 and MCP-1 levels. A 299	
decrease in the production of TNF-α in atherosclerosis-prone mice has been 300	
reported to diminish the extent of anatomic lesions, even the expression of 301	
MCP-1 in atherosclerotic vessels (Ohta et al., 2005). MCP-1 is one of the key 302	
chemokines that regulate migration and infiltration of monocytes, memory T 303	
lymphocytes, and natural killer cells (Deshmane et al., 2009). Therefore, our 304	
findings, in accordance with previous studies showing the anti-inflammatory 305	
benefits of dietary MUFAs (Finucane et al., 2015; Ortega et al., 2012) and NA 306	
(Lipszyc et al., 2013) separately, suggest that dietary MUFAs + NA may be 307	
atheroprotective in the MetS by contributing to a reduced inflammatory status 308	
and recruitment of leukocytes into the plaque. 309	
 310	
Monocyte-derived macrophages are the most abundant myeloid cell type in 311	
atherosclerotic lesions (Hilgendorf, Swirski, & Robbins, 2015). The higher the 312	
number of circulating monocytes increases the risk of monocyte priming-313	
activation and accumulation at sites of inflammation. Prolonged exposure to 314	
hypercholesterolemia has been reported to influence on hematopoietic stem 315	
and multipotential progenitor cells in the bone marrow, leading to over-316	
production of monocytes (Soehnlein & Swirski, 2013; Tolani et al., 2013) and 317	
pointing to a link between haematopoietic hyperactivity with the 318	
atherosclerotic lesion burden (van der Valk et al., 2016). We observed that 319	
HFLCDs rich in MUFAs induced monocytosis but to a lower extent than the 320	
HFLCD rich in SFAs. This effect was unlikely due to serum cholesterol levels, 321	
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as they did not differ among the HFLCDs. Whether triglyceride or fatty acid 322	
sensing pathways, in combination with NA (Montserrat-de la Paz et al., 323	
2016c), orchestrate myelopoiesis requires further investigations. It was also 324	
interesting to observe that HFLCDs rich in MUFAs retained the phenotype of 325	
circulating monocytes with a preponderance of the Ly6Clo subset, which 326	
displays a reduced capacity for plaque invasion and a preferential polarization 327	
into M2 macrophages (Moore, Sheedy, & Fisher, 2013). These Ly6Clo 328	
monocytes were featured by a marked accumulation of the fractalkine 329	
receptor CX3CR1. While all monocytes constitutively express CX3CR1, those 330	
expressing the highest levels of CX3CR1 belong to the non-classical 331	
monocyte subset that barely express the chemoattractant CCR2 (Ancuta et 332	
al., 2003), that actively keep survival signals under both steady-state and 333	
inflammatory conditions (Landsman et al., 2009), and that specifically 334	
participate in wound healing and the resolution of inflammation (Thomas, 335	
Tacke, Hedrick, & Hanna, 2015). In keeping with this notion, atherosclerotic 336	
plaques in animals fed with HFLCDs rich in MUFAs had lower number of 337	
macrophages, much of which exhibiting the M2 phenotype, smaller size, and 338	
less collagen deposition than in animals fed with the HFLCD rich in SFAs. 339	
Importantly, despite the HFLCD-associated monocyte expansion, these 340	
observations and the reduced monocyte expression of CCR2, which is utilized 341	
to enter lesions (Gui, Shimokado, Sun, Akasaka, & Muragaki, 2012; Moore, 342	
Sheedy, & Fisher, 2013), are indicative of a prominent role for dietary MUFAs 343	
+ NA in retaining the abundance of circulating resident/reparative/patrolling or 344	
non-classical monocytes and in lowering the traffic of myeloid cells to plaque 345	




Our study demonstrates that compared to dietary SFAs, MUFAs from olive oil 349	
in combination with NA prevent against atherosclerosis by interfering on 350	
different hallmark events at several independent levels in the setting of MetS. 351	
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Figure 1. (A) Representative FACS plots showing the gating strategy to 519	
identify and quantify the circulating monocyte populations, (B) percentage of 520	
Ly6Clo monocytes over total circulating monocytes, (C) CX3CR1 and (D) 521	
CCR2 expression (MFI, mean fluorescence intensity) in total circulating 522	
monocytes in Lepob/obLDLR−/− mice treated with NA and fed with LFLCD, 523	
HFLCD-SFAs, HFLCD-MUFAs, and HFLCD-PUFAs during 8 weeks. Values 524	
are presented as the mean ± SD (n = 10) and those marked with different 525	
lowercase letter are statistically different (P < 0.05). 526	
 527	
Figure 2. (A) Representative pictures of HE stained sections (original 528	
magnification ×40) and (B) quantification of aortic root plaque area in 529	
Lepob/obLDLR−/− mice treated with NA and fed with LFLCD, HFLCD-SFAs, 530	
HFLCD-MUFAs, and HFLCD-PUFAs during 8 weeks. Scale bar is applicable 531	
to all pictures of the panel (A). Values are presented as the mean ± SD (n = 532	
10) and those marked with different lowercase letter are statistically different 533	
(P < 0.05). 534	
 535	
Figure 3. Representative pictures of Sirius Red stained sections (original 536	
magnification ×40) of aortic root plaque area examined by normal light (A) and 537	
polarized (B) microscopy, (C) percentage of collagen in aortic root plaque 538	
area, and (D) quantification of different collagen fibres per unit of aortic root 539	
plaque area in Lepob/obLDLR−/− mice treated with NA and fed with LFLCD, 540	
HFLCD-SFAs, HFLCD-MUFAs, and HFLCD-PUFAs during 8 weeks. Values 541	
	 23	
are presented as the mean ± SD (n = 10) and those marked with different 542	
lowercase letter are statistically different (P < 0.05). 543	
 544	
Figure 4. Representative pictures of immunohistochemically stained sections 545	
(original magnification ×40) for (A) MAC3, (B) CCR7, and (C) CD163 positive 546	
cells, and percentage of (D) total, (E) M1, and (F) M2 macrophages in aortic 547	
root plaque area of Lepob/obLDLR−/− mice treated with NA and fed with LFLCD, 548	
HFLCD-SFAs, HFLCD-MUFAs, and HFLCD-PUFAs during 8 weeks. Values 549	
are presented as the mean ± SD (n = 10) and those marked with different 550	
lowercase letter are statistically different (P < 0.05).551	
	 24	
Table 1. Fatty acid composition of dietary fats. 
 Cow’s milk cream Refined olive oil 
Refined olive 
oil plus EPA + 
DHA 
Fatty acid g/100 g of fatty acid   
10:0, capric 2.5 ± 0.1 - - 
12:0, lauric 3.1 ± 0.4 - - 
14:0, myristic 10.9 ± 0.9 - - 
16:0, palmitic 35.5 ± 0.8 20.4 ± 0.9 20.5 ± 0.6 
16:1(n-7), palmitoleic 3.6 ± 0.3 1.0 ± 0.2 0.8 ± 0.1 
18:0, stearic 11.5 ± 0.8 5.7 ± 0.1 4.5 ± 0.4 
18:1(n-9), oleic 25.3 ± 0.7 61.9 ± 1.2 61.5 ± 1.0 
18:2(n-6), linoleic 4.3 ± 0.8 8.0 ± 0.7 8.0 ± 0.5 
18:3(n-3), α-linolenic 0.4 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 
20:5(n-3), 
eicosapentaenoic - - 0.9 ± 0.1 
22:6(n-3), 
docosahexaenoic - - 0.7 ± 0.1 
Others 3.0 ± 1.7 2.1 ± 1.1 2.0 ± 0.9 
SFAs 63.5 ± 1.9a 26.1 ± 1.0b 25.0 ± 0.9b 
MUFAs 28.9 ± 0.8b 62.8 ± 1.4a 62.4 ± 1.0a 
PUFAs 4.7 ± 0.8c 9.0 ± 0.7b 10.6 ± 0.7a 
Values are expressed as the mean ± SD (n = 3) and those marked with 




Table 2. Food intake, final body and relative weights, and biochemical blood 
analysis of Lepob/obLDLR−/− mice treated with NA and fed with LFLCD, 
HFLCD-SFAs, HFLCD-MUFAs, and HFLCD-PUFAs during 8 weeks. 
 LFLCD HFLCD-SFAs HFLCD-MUFAs HFLCD-PUFAs 
Food intake 
(g/wk/animal) 26.2 ± 4.4
a 32.8 ± 7.6a 29.6 ± 10.6a 31.77 ± 7.4a 
Final body weight (g) 28.6 ± 2.7c 38.5 ± 2.3a 32.4 ± 1.1b 31.7 ± 1.8b 
Body weight gain (g)  9.0 ± 0.7c 18.4 ± 1.6a 11.7 ± 0.3b 11.0 ± 1.1b 
Biochemical blood parameters 
TC (mmol/L) 3.6 ± 0.2b 4.3 ± 0.3a 4.1 ± 0.2a 4.0 ± 0.1a 
TGs (mmol/L) 0.4 ± 0.1c 0.8 ± 0.1a 0.5 ± 0.1b 0.5 ± 0.1b 
Glucose (mg/dL) 138.2 ± 6.7a 147.5 ± 4.9a 143.8 ± 7.3a 151.5 ± 4.9a 
Insulin (pg/mL) 412.5 ± 92.0d 1103.7 ± 105.1a 873.3 ± 82.7b 707.3 ± 92.2c 
TNF-α (pg/mL) 4.0 ± 0.2b 4.7 ± 0.2a 4.2 ± 0.1b 4.2 ± 0.1b 
IL-6 (pg/mL) 2.9 ± 0.2c 9.7 ± 1.0a 5.0 ± 0.4b 4.7 ± 0.3b 
MCP-1 (pg/mL) 32.9 ± 2.3b 41.0 ± 3.3a 38.2 ± 2.1a 38.4 ± 2.7a 
Values are expressed as the mean ± SD (n = 10) and those marked with 
different lowercase letter in the same row are statistically different (P < 0.05). 
 




